<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568594</url>
  </required_header>
  <id_info>
    <org_study_id>CAPL180A2201</org_study_id>
    <nct_id>NCT00568594</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)</brief_title>
  <official_title>A First-in-human, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose (Healthy Volunteers and CHD Patients) and Multiple Dose (CHD Patients) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180&#xD;
      administered as a single intravenous infusion in healthy volunteers, and (2) the safety,&#xD;
      pharmacokinetics and pharmacodynamics of single and multiple daily intravenous infusions of&#xD;
      APL018 in patients with CHD&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability, pharmacokinetics and effects on biomarkers of HDL function of APL180 after a single and 7-daily infusions in healthy volunteers (HV) and in patients with coronary heart disease (CHD)</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic/pharmacodynamic relationship after a single and 7 daily infusions in CHD patients</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL180</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female healthy volunteers (ages 18-55 years) and patients with CHD (ages 18&#xD;
             to 75 years) on stable statin therapy for at least 8 weeks, with normal liver and&#xD;
             kidney function.&#xD;
&#xD;
          -  Women who are post-menopausal, surgically sterile, or practicing effective&#xD;
             contraception. Additional birth control details to be provided at screening.&#xD;
&#xD;
          -  Body mass index (BMI) must be within the range of 20 to 35 for CHD patients or CHD&#xD;
             equivalents.&#xD;
&#xD;
          -  Clinical CHD:&#xD;
&#xD;
          -  Myocardial infarction (MI), angina, revascularization (e.g. CABG, stent) at least 6&#xD;
             months prior to inclusion&#xD;
&#xD;
          -  CHD equivalents:&#xD;
&#xD;
          -  symptomatic carotid artery disease (e.g. transient ischemic attack or stroke of&#xD;
             carotid origin) or peripheral artery disease or abdominal aortic aneurysm or Diabetes&#xD;
             Mellitus (HbA1c ≤9)&#xD;
&#xD;
          -  20% 10 year risk of CHD (Framingham point score: ≥16 (men), ≥23 (women))&#xD;
&#xD;
          -  Other clinical forms of atherosclerotic disease including &gt;50 percent stenosis on&#xD;
             angiography or ultrasound&#xD;
&#xD;
          -  Male subjects, when sexually active, using one form of highly effective contraception&#xD;
             (e.g. condom)&#xD;
&#xD;
        Exclusion Criteria for both healthy volunteers and patients:&#xD;
&#xD;
          -  Smokers (use of tobacco products in the previous 3 months). Smokers who report&#xD;
             cigarette use of more then 10 cigarette per day or have a urinary cotinine level&#xD;
             greater then 500 ng/ml.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Use of any prescription drugs within four (4) weeks prior dosing, or over-the-counter&#xD;
             (OTC) medication (vitamins, herbal supplements, dietary supplements) within two (2)&#xD;
             weeks prior to dosing. Significant illness within two weeks prior to dosing.&#xD;
&#xD;
          -  Significant illness within two weeks prior to dosing.&#xD;
&#xD;
          -  A past medical history of clinically significant ECG abnormalities or a family history&#xD;
             of a prolonged QT-interval syndrome.&#xD;
&#xD;
          -  History of clinically significant drug allergy or history of atopic allergy (asthma,&#xD;
             urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs&#xD;
             similar to the study drug or any allergic reaction to prior receipt of protein&#xD;
             therapies or vaccines.&#xD;
&#xD;
          -  Presence of NYHA Class III or IV CHF or unstable angina pectoris.&#xD;
&#xD;
          -  MI or within angioplasty (including stenting), acute coronary syndrome (ACS), unstable&#xD;
             angina or arterial embolic disease within 6 months prior to dosing.&#xD;
&#xD;
          -  Use of certain medications prohibited by the protocol.&#xD;
&#xD;
          -  Uncontrolled diabetes (HbA1c &gt; 9).&#xD;
&#xD;
          -  Uncontrolled hypertension (Systolic BP &gt;160 mm Hg and/or Diastolic BP &gt;100 mmHg on two&#xD;
             consecutive measurements).&#xD;
&#xD;
          -  Liver or kidney disease confirmed by abnormal lab values or function.&#xD;
&#xD;
          -  Serum creatine kinase CK (CPK) total &gt; 2x.&#xD;
&#xD;
          -  CHD equivalent patients with a history of early positive exercise stress test.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NOVARTIS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis investigative site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Birkeroed</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Tzrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3320</url>
    <description>Results for CAPL180A2201 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <disposition_first_submitted>October 22, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 22, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 29, 2012</disposition_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apolipoprotein A-I,</keyword>
  <keyword>Atherosclerosis,</keyword>
  <keyword>HDL,</keyword>
  <keyword>Inflammation,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

